You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 699 A differentiated anti-OX40 agonist BGB-A445 does not block OX40-OX40L interaction and reveals remarkable anti-tumor efficacy in preclinical models

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Novel single-agent immunotherapies
699 A differentiated anti-OX40 agonist BGB-A445 does not block OX40-OX40L interaction and reveals remarkable anti-tumor efficacy in preclinical models

 

Online download statistics by month:

Online download statistics by month: November 2020 to June 2025

AbstractFullPdf
Nov 2020177031
Dec 20204206
Jan 20212404
Feb 202134013
Mar 202152012
Apr 202162017
May 20218013
Jun 20210019
Jul 20210022
Aug 20210028
Sep 20210020
Oct 202145032
Nov 202162024
Dec 202144014
Jan 202236011
Feb 202255010
Mar 202276019
Apr 202266022
May 202272040
Jun 2022135011
Jul 202272013
Aug 2022101015
Sep 202266022
Oct 20224505
Nov 202272014
Dec 202271010
Jan 202344019
Feb 202311606
Mar 202392013
Apr 20233806
May 20237209
Jun 202380020
Jul 202370011
Aug 20234405
Sep 20232206
Oct 20234605
Nov 202352012
Dec 20238209
Jan 20242000
Feb 20245002
Mar 20246005
Apr 202450014
May 20243806
Jun 202430021
Jul 202428026
Aug 202434028
Sep 202454013
Oct 202426020
Nov 202432011
Dec 202417016
Jan 202546011
Feb 20252016
Mar 20250017
Apr 2025006
May 2025005
Jun 2025007
Total26620792